Swiss Researchers Launch Four-Year Study Into Light-Activated Nanozymes for Aggressive Astrocytoma Treatment

Empa researchers develop light-triggered nanozymes to treat astrocytoma. This Swiss-led project aims to bypass the blood-brain barrier for precise cancer therapy.

By: AXL Media

Published: Apr 30, 2026, 5:16 AM EDT

Source: Information for this report was sourced from News-Medical.net and Empa

The Challenge of Invasive Brain Malignancies

Astrocytoma remains one of the most lethal forms of brain cancer due to its highly aggressive growth pattern and its tendency to invade healthy surrounding tissue. Current medical data indicates a grim prognosis for patients, with a five-year survival rate of approximately five percent and a recurrence rate as high as 70 percent. Surgical removal is often insufficient because microscopic cancer cells frequently remain embedded in sensitive brain structures. To address this, a Swiss research initiative led by neurosurgeon Isabel Hostettler is pioneering a novel therapeutic approach that moves beyond traditional radiation and chemotherapy, focusing instead on precision-targeted nanomedicine applied directly to the tumor site.

Bypassing the Brain’s Natural Defenses

One of the primary obstacles in treating neurological cancers is the blood-brain barrier, a protective filter that prevents toxins, and many life-saving drugs, from reaching the brain via the bloodstream. Empa researcher Giacomo Reina and his team are developing a strategy to circumvent this barrier by applying biocompatible nanomaterials during active tumor surgery. Because cancer cells possess a significantly more active metabolism than healthy tissue, these "nanozymes" naturally accumulate within the malignant areas. This localized delivery ensures that high concentrations of the therapeutic agent reach the target without the systemic toxicity often associated with intravenous chemotherapy.

Precision Activation via Infrared Light

The unique advantage of these nanozymes lies in their activation mechanism. These materials are designed to remain dormant until they are exposed to near-infrared light, allowing surgeons to control exactly when and where the treatment becomes active. This light-based trigger allows for a "gentle but powerful" effect, minimizing damage to adjacent healthy brain tissue. Once activated, the nanozymes mimic natural enzymes to catalyze chemical reactions, such as generating reactive oxygen compounds that specifically destroy the internal structures of the tumor cells while sparing the surrounding neural architecture.